ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Dec 4, 2025

ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise

Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients

GlobeNewsWire • Dec 2, 2025

ANI Pharmaceuticals Announces Board Transition

Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board

GlobeNewsWire • Dec 1, 2025

Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?

Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.

Zacks Investment Research • Nov 28, 2025

ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?

ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.

Zacks Investment Research • Nov 28, 2025

ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET.

GlobeNewsWire • Nov 25, 2025

Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth

ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.

Zacks Investment Research • Nov 21, 2025

ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Nov 19, 2025

ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know

ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Nov 18, 2025

3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)

ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Nov 18, 2025